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In popular medicine Silybum marianum is used as a hepatoprotective agent. Silymarin is the major constituent. 
The present work deals with the formulation and evaluation of S. marianum tablets from ethanolic extract by 
direct compression. The ethanolic extract was obtained from seeds by soxhlet extraction. Two pharmaceutical 
formulations were prepared using fluid extract as an active principle, and Aeroperl® 300 Pharma as a carrier. In 
order to improve flow ability and compressibility, co-processed excipients MicroceLac® 100 and FlowLac® 90 
were employed. Pre-compression and post-compression parameters were evaluated according to USP 34-NF 
29. Besides, silymarin was determined by NMR spectral data. Both formulations showed excellent rheological 
properties and the best biopharmaceutical parameters were observed in F2 (S. marianum ethanolic extract, 
aeroperl® 300 Pharma, flowLac® 90, glycolate starch and magnesium stearate) in terms of the friability (0.82 
%) and the disintegration time (8.05 min).
Key words: direct compression, ethanolic extract, herbal tablets, quality controls, Silybum marianum.
Resumen 
En medicina popular, Silybum marianum se usa como agente hepatoprotector. La silimarina es su componente 
principal. El presente trabajo trata de la formulación y evaluación de tabletas de S. marianum a partir de 
extracto etanólico por compresión directa. El extracto etanólico se obtuvo de las semillas mediante extracción 
con soxhlet. Se prepararon dos formulaciones farmacéuticas usando extracto fluido como principio activo 
y Aeroperl® 300 Pharma como vehículo. Para mejorar la capacidad de flujo y la compresibilidad, se 
emplearon excipientes coprocesados MicroceLac® 100 y FlowLac® 90. Los parámetros de precompresión y 
postcompresión se evaluaron de acuerdo con USP 34-NF 29. Además, la silimarina se determinó mediante 
datos espectrales de RMN. Ambas formulaciones mostraron excelentes propiedades reológicas y los mejores 
parámetros biofarmacéuticos se observaron en F2 (S. marianum ethanolic extract, aeroperl® 300 Pharma, 
flowLac® 90, glicolado de almidón y estearato de magnesio) en términos de friabilidad (0,82%) y el tiempo 
de desintegración (8,05 min).
Palabras clave: compresión directa, extracto etanólico, comprimidos herbarios, controles de calidad, Silybum 
marianum.
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Introduction
Silybum marianum (L.) Gaertn, “cardo 
mariano”, is employed in popular medicine as a 
hepatoprotective herbal medicine (Flora et al. 1998; 
Freitag et al. 2015; Bouhalit & Kechrid 2018). A 
set of flavolignans, called silymarin, are the main 
active ingredients of S. marianum extract: silybin A 
and B (I), isosilybin A and B (I) and silychristin (II) 
(Fig. 1). Silymarin is poorly soluble in water and it is 
usually administered in oral forms (Ramírez-Santos 
et al. 2011; Shakeela et al. 2014). 
The proposed dose of silymarin in the tablets 
is approximately the dose contained in one cup of tea 
prepared from 2 g of vegetable drug (Alonso 2004).
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In the Argentinean market, silymarin is present 
under the form of tablets obtained by wet granulation 
(Laragon 150 commercial tablets, Roemmers (CT)); 
however, S. marianum herbal tablets obtained by 
dry route and direct compression are not available.
In recent years, the use of herbal medicinal 
products has increased in importance across the 
world and novel pharmaceutical formulations are 
required (WHO 2004). Tablets are the most common 
solid pharmaceutical dosage formulation used by 
humans and they are conventionally prepared by wet 
granulation (WG), dry granulation (DG) and direct 
compression (DC) (Vila Jato 2001). DC produces 
tablets with faster dissolution times and requires a 
smaller number of production steps (Remington 
2003). Aeroperl® 300 Pharma is an excellent 
pharmaceutical absorbent for direct compression. 
This hydrophilic fumed silica is used as carrier in 
solid dosage forms since it allows the incorporation 
of fluid extracts and at the same time it improves 
dissolution of poorly soluble active principles (Desai 
2016; Wei et al. 2017). 
Direct compression formulations consist 
of four basic ingredients: a diluent to increase 
the bulk, a lubricant to improve flow of blend, a 
disintegrant to improve the biodisponibility and the 
active ingredient (Singh et al. 2004). The excipients 
have to compensate for poor flow and compression 
properties, which are often inherent to the active 
extract (Jivraj et al. 2000; Shubhajit & Changquan 
2018). In this sense, lactose co-processed excipients 
improve process ability, performing as diluent 
and disintegrant agents (Villafuerte Robles 2011; 
Mamatha et al. 2017).
In the present work we report a novel 
formulation to obtain herbal tablets of S. marianum 
by direct compression using MicroceLac100® 
(75% alpha-lactose monohydrate and 25% 
microcrystalline cellulose) and FlowLac90® 
(spray-dried alpha-lactose monohydrate) as lactose 
co-processed excipients. Also, starch glycolate was 
used as a superdisintegrant and magnesium stearate 
as a lubricant.
In addition, the NMR fingerprint of tablets 
prepared with silymarin was made.
Materials and Methods
Silymarin, organic solvents, chemicals and 
reagents of analytical grade were purchased from 
Sigma-Aldrich. The direct compression excipients 
investigated in this study included: Aeroperl® 
300 Pharma, MicroceLac® 100 and FlowLac® 90 
(Meggle Pharma, Germany) and were donated 
by Etilfarma. Glycollate starch and magnesium 
stearate were purchased from Droguería Saporiti 
S.A.C.I.F.I.A.
The seeds of Silybum marianum were 
purchased in an herbal shop from the city of San Luis 
(Argentina) and were identified as genuine by macro 
and microscopic techniques. The ethanolic extract 
was obtained by following official methods. The 
quantitative analysis of silymarin was performed 
by UV-vis spectrophotometric method (UV-vis 
Spectrophotometer, Beckman, DU-640) (Gul et al. 
2015). Concentration of silymarin was determined 
as 1.96 mg/mL from the calibration curve.
Granulate was obtained by immersing the 
extract in Aeroperl® used as a carrier, in a 1:1 ratio 
(Sun et al. 2018). The evaporation of the solvent 
was carried out under reduced pressure and then 
dried in an oven (40 oC) to constant weight. Two 
tablet formulations (F1 and F2) were proposed using 
different diluents (FlowLac 90® and MicroceLac® 
100, respectively) (Tab. 1).
The dynamic for each mixture of powder 
was determined by the funnel method as described 
in the literature (Lantz & Schwartz 1990). To 
determine the density of the samples, the powder 
Figure 1 – Major flavolignans present in silymarin.
Silybum marianum tablets 3 de 9
Rodriguésia 71: e00832019. 2020
was gently poured into 10 cm3 graduate cylinder 
to a total volume of 10 cm3. The bulk density 
(DB) was calculated as the ratio between weight 
(g) and volume (cm3). To determine the final 
tapped density (DT) the cylinder was tapped with 
1 inch vertical drop, at 1 second interval, until no 
measurable change in volume was noticed. The 
compressibility of the powder was evaluated using 
the Hausner Ratio (HR) (Schmidt & Rubensdörfer 
1994) (Tab. 2).




Silybum marianum ethanolic extract (mL/tablet) 26 26
Aeroperl® 300 Pharma (mg/tablet) 26 26
MicroceLac® 100 (mg/tablet) 74.1 -----
FlowLac® 90 (mg/tablet) ----- 74.1
Glycolate starch (mg/tablet) 2.6 2.6




Bulk density (g/cm3) 0.54 ± 0.003 0.59 ± 0.001
Tapped density (g/cm3) 0.62 ± 0.004 0.67 ± 0.013
Compressibility (%) 14.39 ± 0.54 12.05 ± 0.005
Hausner ratio 1.16 ± 0.005 1.14 ± 0.02
Angle of repose (θ) 10.23 ± 1.2 8.7 ± 0.45
Table 2 – Densities and flow properties of physical mixtures containing Silybum marianum ethanolic extract.
The values represent the mean of three determinations ± standard deviation.
The extract and excipients, except the 
magnesium stearate, were blended for 10 minutes 
by tumbling, then the corresponding amount 
of magnesium stearate was added and blended 
for five more minutes; and after that, they were 
compressed by using a mini-press mono-punch 
eccentric machine, with a punch set of 7.0 mm 
in diameter during 4 minutes. The weight of 
each tablet was 130 mg (Fig. 2). Tablet hardness 
was measured with a Scout hardness tester. The 
tablets previously weighted were loaded into a 
friabilator USP (Electrolab Dual Drum Friability 
Tester EF-2) and the friability was evaluated in 
accordance with USP 34-NF 29 (USP 2011). 
Friability (%) = (W1- W2/ W1) x 100. (W1 = 
weight of tablets before testing and W2 = weight 
of tablets after testing).
Figure 2 – Prepared tablets from Silybum marianum 
ethanolic extract.
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The disintegration test was conducted 
following the method established by the USP 
(USP 2011). A tablet disintegration test apparatus 
(Electrolab disintegration tester DT2L) was 
used to determine the disintegration time for all 
formulations. Six tablets were placed individually 
in each tube of the disintegration test apparatus. The 
phosphate medium was maintained at a temperature 
of 37 ± 2 ºC and the time was noted for the entire 
tablet to complete disintegration.
A USP dissolution test apparatus (Hanson 
Research SR8PLUS) type II was used for the 
in vitro dissolution test. First, 900 mL of the 
phosphate buffer pH 7.5 with 2% of sodium lauryl 
sulfate was placed in a vessel, and the temperature 
was maintained at 37 ± 0.5 ºC. The speed of the 
paddle was fixed at 100 rpm. Dissolution samples 
were then withdrawn at 5 minute intervals. Drug 
concentration was calculated by measuring the 
absorbance at 287 nm from the standard calibration 
curve previously obtained using silymarin (Sigma-
Aldrich) and expressed as a percentage of the 
cumulative drug dissolved. The test was performed 
in triplicate (USP 2011). 
The quantitative analysis of silymarin in F1, 
F2 and in Laragon 150 commercial tablets (CT) 
was performed by spectrophotometry (Meghreji 
et al. 2010). All determinations were made in 
triplicate.
Five tablets of F1, F2 and CT were finely 
powdered. An amount of the powdered tablet 
equivalent to 50 mg/tablet (F1, F2) and 150 mg/
tablet (CT) of silymarin were weighed accurately, 
and extracted into 3 × 20 ml portions of chloroform 
with shaking. The residue was filtered using 
Whatmann No. 42 filter paper. The filtrate was 
evaporated to dryness under vacuum and the 
remaining drug was dissolved in methanol and 
diluted to 100 mL. The final concentration of 
silymarin was about 0.5 mg/mL (F1, F2) and 1.5 
mg/mL (CT). Suitable dilutions were done with 
methanol before measurements. As a positive 
control was used CT because it is developed by a 
leader laboratory.
NMR (1H-, 13C- and 13C 1H HSQC) spectral 
data of F2, CT and silymarin were obtained in a 
Bruker Spectra AC-200 (200 MHz, 50 MHz) in 
Acetone-d6 (Lee & Liu 2003; Liu & Lee 2012).
All results were expressed as mean values ± 
standard deviation (SD). The dissolution data was 
subject to statistical analysis using a computer 
program, Graphpad INSTAT tm Copyright 
1990–1993 (2.04 version, Ralf Stahlman, Purdue 
University, USA, 931897S) for a one-way analysis 
of variance (ANOVA). P < 0.05 was considered as 
evidence of a significant difference.
Results and Discussion
In the present study, the ethanolic extract 
of Silybum marianum was employed as an 
active ingredient to design, develop and evaluate 
tablets by direct compression. The fluid extract 
was obtained by soxhlet extraction and the 
concentration of silymarin was determined by 
UV-visible spectrometry (1.96 mg/mL) (Gul et 
al. 2015). 
Two appropriate formulations for direct 
compression were prepared. Their compositions 
are shown in Table 1. Both formulations have S. 
marianum extract as active ingredient. Because 
silymarin has poor solubility, Aeroperl® 300 
Pharma was used as carrier. The liquid crude 
extract of the plant was adsorbed by immersing it 
in granulated colloidal silicon dioxide (Aeroperl® 
300 Pharma) in 1:1 relation. In addition, two lactose 
excipients of pharmaceutical degree, frequently 
used in direct compression, were employed as 
diluent agents: MicroceLac® 100 and FlowLac® 90. 
Both derive from nature and are frequently used as 
diluent/binder agents in oral dosage. These kinds of 
co-processed excipients provide a better tableting 
performance (Lamešićet al. 2017; Mužíková et 
al. 2018).
On the other hand, pre-compression and post-
compression parameters were evaluated according 
to official standards. Table 2 shows the densities 
and flow properties of physical mixtures containing 
S. marianum ethanolic extract. The powders of 
both formulations flowed very well, given that 
the corresponding angles of repose between 7º and 
13º were less than 25º. The experimental values 
indicated that both powder mixtures possess good 
flow properties and good packing ability, and at 
the same time they meet the official requirements 
(Lantz & Schwartz 1990).
The tablets were obtained by direct 
compression using a mono-punch eccentric 
machine with 7 mm-diameter punches (Fig. 2). The 
prepared tablets were evaluated for uniformity of 
weight, hardness, friability and disintegration time. 
The experimental results obtained are shown in 
Table 3. Both batches of the manufactured tablets 
were acceptable according to the US pharmacopeia. 
The variation in weight was less than 10% (USP 
2011). This parameter confirmed the consistency 
of dosage units during compression. As soon as to 
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friability, both formulations had a loss weighing less 
than 1%, which would determine a higher resistance 
to abrasion. In relation to the disintegration time, F2 
showed the lowest value that would be related with 
their lower hardness value. Hardness is an important 
parameter to estimate the disintegration time, since 
the resistant tablets do not disintegrate in the time 
required to satisfy the dissolution specifications 
(Da Silva Solon et al. 2010). 
The content of silymarin in F1, F2 and CT 
was shown in Table 4. All the formulations were 




Weight variation (mg) 129.7 ± 1.05 134.2 ± 0.61
Friability (%) 0.92 ± 0.015 0.82 ± 0.03
Disintegration time (min) 19.4 ± 0.15 8.05 ± 0.03
Hardness (kg/cm2) 4.40 ± 0.11 3.70 ± 0.17
Table 3 – Results of control tests performed on Silybum marianum tablet.
The values represent the mean of three determinations ± standard deviation.
Formulation Silymarin Nominal quantity (mg) Silymarin Found (mg) ± SD
F1 50 49.16 ± 0.0059
F2 50 50.47 ± 0.0067
CT 150 150.30 ± 0.0031
Table 4 – Analysis of silymarin in S. marianum tablet formulations (F1, F2) and commercial tablets (CT).
Figure 3 – In vitro dissolution profiles test of S. 
marianum tablet formulations (F1, F2) and commercial 
tablets (CT). profiles test.
Moreover, the cumulative amount of drug 
released over time was calculated for both 
formulations. The in vitro dissolution profiles 
are shown in Figure 3. At 45 minutes Q (%) the 
experimental values were: 96.430 ± 0.101 (CT), 
86.589 ± 0.003 (F2) and 67.533 ± 0.088 (F1). 
The dissolution test for tablets described in the 
USP indicates that no less than 75% of silymarin 
content should be dissolved in 45 minutes. 
Consequently, F2 and CT satisfied this official 
specification, evidencing their excellent galenic 
and pharmacokinetic features. Additionally, F2 
presented parameters of in vitro release closer to 
CT. These results could be attributed to the absence 
of microcrystalline cellulose in F2.
Furthermore, mono and bi-dimensional 
NMR techniques were used to identify silymarin 
in the manufactured tablets (F2). These data were 
identified and compared with silymarin from 
CT and with silymarin Sigma-Aldrich (Kim et 
al. 2003; Bijak 2017). 1H-NMR fingerprint is a 
useful secondary quality assurance method for 
the standardization of silymarin. In the 1H-NMR 
spectrum of F2, in accordance with the information 
provided by the literature and compared with CT 
and with silymarin Sigma-Aldrich, the presence 
of the major constituents was divided into eight 
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areas (A-H) (Fig. 4). Each area clearly represented 
the structural features of flavolignans informed 
in the literature. The assignment of areas A-H is 
summarized in Table 5. Among these eight areas, 
area C represents the unique signal of H-7”of 
silychristin (II) at 5.61 ppm (d, J = 7Hz). Area F 
Figure 4 – 1H NMR spectrum of S. marianum tablet formulation (F2), commercial tablets (CT) and silymarin).
Areas Protons Assignment
A (δ 6.80~7.20) H-2’, H-5’, H-6’ Silybin A and B (I), Isosilybin A and B (I), Silychristin (II).
B (δ 5.93~6.05) H-6, H-8 Silybin A and B (I), Isosilybin A and B (I), Silychristin (II).
C (δ 5.56~5.60) H-7” Silychristin (II).
D (δ 4.95~5.15) H-2 Silybin A and B (I), Isosilybin A and B (I), Silychristin (II).
H-7” Silybin A and B (I), Isosilybin A and B (I).
E (δ 4.60~4.70) H-3 Silybin A and B (I), Isosilybin A and B (I), Silychristin (II).
F (δ 4.10~4.25) H-8” Silybin A and B (I), Isosilybin A and B (I).
G (δ 3.72~3.90)
OCH3 Silybin A and B (I), Isosilybin A and B (I), Silychristin (II).
H-9” Silybin A and B (I), Isosilybin A and B (I), Silychristin (II).
H (δ 3.40~3.70) H-8” Silychristin (II).
H-9” Silybin A and B (I), Isosilybin A and B (I), Silychristin (II).
Table 5 – 1H-NMR fingerprint of silymarin.
only contributed to H-8” of silybin A and B (I), 
isosilybin A and B (I) at 4.15 ppm as multiplet. 
From 2D 13C1H-HSQC twelve regions were 
determined in the 13C-NMR fingerprint of silymarin 
of prepared tablets, compared with CT and 
silymarin Sigma-Aldrich (Fig. 5). The assignment 
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of areas A-J is shown in Table 6. Among these 
areas, four were characteristic areas: area C (C-7”, 
dC 88.67, d) of silychristin (II); area D2 (C-7’, dC 
77.35, d) of silybin A and B (I), isosilybin A and 
B (I); area F (C-8”, dC 79.73, d) of silybin A and 
B (I), isosilybin A and B (I) and area H1 (C-8”, 
dC56.48, d) of silychristin (II). 13C-NMR fingerprint 
takes advantage of the fact that samples contain 
Figure 5 – 13C NMR spectrum of S. marianum tablet formulation (F2), commercial tablets (CT) and silymarin.
Areas Carbons Assignment
 A (δ 114.05~122.03) C-2’, C-5’, C-6’ Silybin A and B (I), Isosilybin A and B (I), Silychristin (II).
B (δ 96.17~97.24) C-6, C-8. Silybin A and B (I), Isosilybin A and B (I), Silychristin (II).
C (δ 88.67) C-7” Silychristin (II).
D1 (δ 84.20) C-2 Silybin A and B (I), Isosilybin A and B (I), Silychristin (II).
D2 (δ 77.35) C-7” Silybin A and B (I), Isosilybin A and B (I).
E (δ 73.25) C-3 Silybin A and B (I), Isosilybin A and B (I), Silychristin (II).
F (δ 79.73) C-8” Silybin A and B (I), Isosilybin A and B (I).
G (δ 55.58) OCH3 Silybin A and B (I), Isosilybin A and B (I), Silychristin II).
H1 (δ 56.48) C-8” Silychristin (II).
H2 (δ 61.95) C-9” Silybin A and B (I), Isosilybin A and B (I), Silychristin (II).
I (δ 101.62) C-10 Silybin A and B (I), Isosilybin A and B (I), Silychristin (II).
J (δ 129.31~198.19) C-9, C-5, C-7, C-4, C-1’, 
C-3’, C-4’, C-1”, C-3”, C-4”
Silybin A and B (I), Isosilybin A and B (I), Silychristin (II).
Table 6 – 13C-NMR fingerprint of silymarin.
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simplified profiles with minimal signal overlap 
(Sharmin & Zafar 2017).
In conclusion, the formulation prepared in 
this study F2 showed excellent technology and 
quality parameters. This formulation could be 
used for herbal tablets of fluid extracts with poorly 
soluble actives, such as silymarin, ensuring their 
stability by avoiding heat and humidity factors 
during the manufacturing process.
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